Author + information
Metabolic syndrome (MS) is a condition linking insulin resistance, dyslipidemia, hyperglycemia, and hypertension that increases the risk of developing diabetes, cardiovascular disease, and subsequent cardiovascular morbidity and mortality. We aimed to study the effect of metabolic syndrome (MS) on short-term outcomes after coronary artery stenting with drug-eluted stents (DES).
We have investigated 132 patients with MS (m=61; mean age 61.4 years old) compared to those of 52 patients without it (m=27; mean age 61.8 years old) in the interventional cardiology department of the Republican specialized scientific-practical medical center of therapy and medical rehabilitation. Metabolic syndrome was defined by the “Harmonized definition of the MS”. The medium follow-up period was 2.8 years. A composite event consisted of repeat revascularization, non-fatal myocardial infarction, and cardiac death.
MS components showed a significant relationship to the composite event. When compared with no MS factors, the adjusted hazard ratio for one and five MS components was 1.32 (95% CI: 0.91–1.78) and 1.82 (1.24–2.82), respectively. Cox regression analysis showed that MS as a significant predictor of major adverse cardiovascular events.
Metabolic syndrome increases composite event risk in patients who have undergone coronary artery stenting with DES. The risk is worse with increasing number of MS components.